InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
22%
T+90 mean return
-6.4%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by PITZER KENNETH R, Deputy Chief Executive. Director active across 1 company, notably Theravance Biopharma, Inc.. In total, 9 disclosures have been published. Activity tracked since 20 May 2021. The latest transaction was disclosed on 18 February 2022 (Retenue fiscale). Regulator: SEC (Form 4). All data is openly available.
Declarations9 total
27,299 shares@ US$9.610.028% mcap44.1% of flowOrdinary SharesSEC:0001415889-22-001701:0
52,000 shares0Ordinary SharesSEC:0001415889-22-001184:0
52,000 shares0Ordinary SharesSEC:0001415889-22-001184
4,310 shares@ US$8.360.0038% mcap6.1% of flowOrdinary SharesSEC:0001415889-21-005469:0
4,310 shares@ US$8.366.1% of flowOrdinary SharesSEC:0001415889-21-005469
4,307 shares@ US$14.050.0062% mcap9.9% of flowOrdinary SharesSEC:0001179110-21-008398:0
4,307 shares@ US$14.059.9% of flowOrdinary SharesSEC:0001179110-21-008398
4,310 shares@ US$17.8012.0% of flowOrdinary SharesSEC:0001179110-21-005846
4,310 shares@ US$17.800.0075% mcap12.0% of flowOrdinary SharesSEC:0001179110-21-005846:0
9 of 9 declarations
About PITZER KENNETH R
Kenneth R. Pitzer is Senior Vice President, Head of Product Strategy and Communication Planning at Theravance Biopharma, Inc., a biopharmaceutical company. In his role, he oversees product and communication strategies, contributing to the company's innovation. His expertise is essential for Theravance in its mission to improve healthcare.
